Akari Therapeutics Plc (AKTX)
0.2111
-0.02
(-7.90%)
USD |
NASDAQ |
Mar 16, 10:54
Akari Therapeutics Enterprise Value : 10.07M for March 13, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| DBV Technologies SA | 1.074B |
| Cellectis SA | 271.02M |
| Biodexa Pharmaceuticals Plc | -- |
| Mereo BioPharma Group Plc | 13.07M |
| Evaxion AS | 24.96M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -6.36M |
| Total Expenses (Quarterly) | 6.36M |
| EPS Diluted (Quarterly) | -0.1947 |
| Earnings Yield | -185.4% |